Prurigo form of atopic dermatitis
Conditions
Interventions
All patients will be randomized to a within-patient left-right comparison study of excimer laser versus topical clobetason propionaat. Treatment with the ecximer laser will be performed twice a week,
Sponsors
Academic Medical Center, University of Amsterdam, Dept. of Dermatology
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adult patients (>18 years old); 2. Prurigo form of atopic dermatitisbased on: 2.1 Hanifin and Rajka criteria fullfilled; 2.2 Presence of allergen specific IgE; 2.3 Lasting for at least 6 months; 2.4 Refractory to the standard therapy; 2.5 At least 4 symmetrical nodules; 3. Upper or lower extremities affected; 4. Written informed consent provided.
Exclusion criteria
Exclusion criteria: 1. Patients unable to comply with the requirements of the study; 2. Female patients who are pregnant or breastfeeding; 3. Patients treated with sedating antihistamines within 24hrs before start of study treatment; 4. Patients treated with topical steroids within one week before start of study treatment; 5. Patients treated with phototherapy or PUVA within one week before start of study treatment; 6. Patients treated with systemic therapy that might have an effect on the prurigo form of AD within 4 weeks before start of study treatment; 7. Patients with hypersensitivity to the study treatment or sunlight; 8. Patients receiving drugs known to cause photosensitivity and/or photo toxicity; 9. Patients with any other interfering skin diseases, which jeopardize the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical responses will be evaluated using Physician assessment of individual signs (number of nodules, elevation of nodules, excoriation, erythema and pruritus). | — |
Secondary
| Measure | Time frame |
|---|---|
| Photographic documentation, Physician Global assessment (PGA) and Patient Global Assessment (PaGA) will be evaluated. Besides the clinical responses, the patient and physician satisfaction/preference and duration of remission will be evaluated. | — |
Contacts
Public ContactE.E.A. Brenninkmeijer
Academic Medical Center Amsterdam (AMC) Department of Dermatology, A0-223 P.O. Box 22660
Outcome results
None listed